Header

UZH-Logo

Maintenance Infos

The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors


Nurmi, Visa; Knight, Chanice; Estcourt, Lise; Hepojoki, Jussi; Lamikanra, Abigail A; Tsang, Hoi P; Roberts, David J; Polack, Fernando P; Simmonds, Peter; Hedman, Klaus; Alvarez-Paggi, Damian; Harvala, Heli (2023). The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors. Journal of Infectious Diseases, 228(3):245-250.

Abstract

Convalescent plasma (CP) treatment of coronavirus disease 2019 (COVID-19) has shown significant therapeutic effect when administered early (eg, Argentinian trial showing reduced hospitalization) but has in general been ineffective (eg, REMAP-CAP trial without improvement during hospitalization). To investigate whether the differences in CP used could explain the different outcomes, we compared neutralizing antibodies, anti-spike IgG, and avidity of CP used in the REMAP-CAP and Argentinian trials and in convalescent vaccinees. We found no difference between the trial plasmas, emphasizing initial patient serostatus as treatment efficacy predictor. By contrast, vaccinee CP showed significantly higher titers and avidity, being preferable for future CP treatment. Clinical Trials Registration. NCT02735707 and NCT04479163.

Abstract

Convalescent plasma (CP) treatment of coronavirus disease 2019 (COVID-19) has shown significant therapeutic effect when administered early (eg, Argentinian trial showing reduced hospitalization) but has in general been ineffective (eg, REMAP-CAP trial without improvement during hospitalization). To investigate whether the differences in CP used could explain the different outcomes, we compared neutralizing antibodies, anti-spike IgG, and avidity of CP used in the REMAP-CAP and Argentinian trials and in convalescent vaccinees. We found no difference between the trial plasmas, emphasizing initial patient serostatus as treatment efficacy predictor. By contrast, vaccinee CP showed significantly higher titers and avidity, being preferable for future CP treatment. Clinical Trials Registration. NCT02735707 and NCT04479163.

Statistics

Citations

Dimensions.ai Metrics
1 citation in Web of Science®
2 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

1 download since deposited on 29 Dec 2023
1 download since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:05 Vetsuisse Faculty > Veterinärwissenschaftliches Institut > Institute of Veterinary Pathology
Dewey Decimal Classification:570 Life sciences; biology
Scopus Subject Areas:Health Sciences > General Medicine
Uncontrolled Keywords:Infectious Diseases, Immunology and Allergy
Language:English
Date:11 August 2023
Deposited On:29 Dec 2023 10:39
Last Modified:29 Jun 2024 01:41
Publisher:Oxford University Press
ISSN:0022-1899
OA Status:Hybrid
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1093/infdis/jiad070
PubMed ID:36967714
Project Information:
  • : FunderSupport-E
  • : Grant ID
  • : Project Title
  • : FunderNational Institute for Health and Care Research
  • : Grant ID
  • : Project Title
  • : FunderAcademy of Finland
  • : Grant ID
  • : Project Title
  • : FunderFinnish Society for Study of Infectious Diseases
  • : Grant ID
  • : Project Title
  • : FunderNHS Blood and Transplant
  • : Grant ID
  • : Project Title
  • : FunderSigrid Jusélius Foundation
  • : Grant ID
  • : Project Title
  • : FunderMagnus Ehrnrooth Foundation
  • : Grant ID
  • : Project Title
  • Content: Published Version
  • Language: English
  • Licence: Creative Commons: Attribution 4.0 International (CC BY 4.0)